← Back to Team

Houman Ashrafian

Managing Partner

Houmana banner

In his five years at SV, Houman has founded six currently active SV companies. He co-leads SV’s Biotech franchise, which has a long history of building high value, successful new companies and bringing transformational drugs from discovery to market, having joined SV in 2016 as a Venture Partner, been promoted to Partner in 2017 and became a Managing Partner in 2018.

Houman serves on the board of the six companies he has founded; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx and TrexBio as well as on the boards of Therini and Imbria. He also serves on the Dementia Discovery Fund (DDF) Investment Committee.

Previously, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. Heart Metabolics successfully repositioned perhexiline, as a treatment for hypertrophic cardiomyopathy and heart failure. Perhexiline is now in advanced clinical trials and has orphan drug designation. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma.

Outside of SV, following completion of his cardiology training, Houman was appointed as an Honorary Consultant Cardiologist in 2011 at the John Radcliffe Hospital in Oxford. He is Visiting Professor and Head of Experimental Therapeutics at the University of Oxford. Additionally, Houman is co-founder and Chairman of Weatherden, a boutique clinical development company.

Academic credentials

Undergraduate degree, University of Cambridge; BM BCh, DPhil, University of Oxford.


Investing in Women Code Logo

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.